Skip to main content
Equibles
AVIR logo

AVIR · Atea Pharmaceuticals, Inc. · Metrics

Track AVIR — free

Use AVIR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AVIR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.04 -0.01 (-0.25%) At close · Oct 23
Russell 2000 member Rebalance outlook locked
Market Cap
$322.82M
Shares
80.20M
Volume · Oct 23 245.44K Avg daily vol (3M) 313.12K

AVIR metrics

79 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$4.04
Market cap
$322.82M

Price action

20 metrics
Price change (1W)
-6.5%
Price change (30D)
-21.9%
Price change (3M)
-14.6%
Price change (6M)
-26.1%
Price change (YTD)
+13.2%
Price change (1Y)
+26.6%
Trailing year
Price change (5Y)
-68.3%
52-week high
$6.15
52-week low
$2.96
Change from 52-week high
-34.3%
Change from 52-week low
+36.5%
Annualized volatility
51.2%
Annualized volatility (3M)
46.7%
Beta
0.8
RSI (14D)
24.4
Price vs SMA 50
-21.6%
Price vs SMA 200
-17.8%
Avg volume (3M)
313,124
Relative volume
0.8
Average dollar volume
$1.56M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
80.20M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.9×
reciprocal yield 108.8%
P / book
1.6
reciprocal yield 63.2%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-51.2%

Historical valuation

8 metrics
P / E historical average (3Y)
25.9×
reciprocal yield 3.9%
P / E historical average (5Y)
25.9×
reciprocal yield 3.9%
EV / revenue historical average (3Y)
0.0×
EV / revenue historical average (5Y)
0.0×
EV / EBIT historical average (3Y)
11.8×
reciprocal yield 8.5%
EV / EBIT historical average (5Y)
11.8×
reciprocal yield 8.5%
EV / EBITDA historical average (3Y)
14.1×
reciprocal yield 7.1%
EV / EBITDA historical average (5Y)
14.1×
reciprocal yield 7.1%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-12

Profitability

9 metrics
Gross margin
—
Operating margin
39.4%
Trailing 12 months
Net margin
34.5%
Gross profit (TTM)
—
Operating profit (TTM)
−$183.61M
Net income (TTM)
−$165.29M
Trailing 12 months
Diluted EPS (TTM)
$-2.08
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-2.32
EBITDA per diluted share (TTM)
$-2.32
Net income per diluted share (TTM)
$-2.09
Operating cash flow per diluted share (TTM)
$-1.92
Free cash flow per diluted share (TTM)
$-1.48
Capital expenditures per diluted share (TTM)
$0.02
R&D per diluted share (TTM)
$1.97
Stock compensation per diluted share (TTM)
$0.21
Book value per share
$3.53

Growth

11 metrics
Revenue growth YoY
+622.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$351.37M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-4.4%
Year over year · fewer shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-81.0%
Return on assets
-71.2%
Debt / equity
—
Current ratio
8.1
EBITDA (TTM)
−$183.19M
Free cash flow (TTM)
—
Quick ratio
8.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$76.55M
Latest balance sheet
Cash & equivalents
$76.55M
Total assets
$232.28M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$152.07M
Capital expenditures (TTM)
$1.94M
R&D (TTM)
$155.45M
SG&A (TTM)
—
Stock compensation (TTM)
$16.21M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
124
13F filer change QoQ
-3
Institutional ownership
74.1%
Conviction holders (share of 13F filers)
0.8%
Crowding (high-turnover and private-fund holders)
16.9%
Private-fund adviser ownership
16.3%
Active holders' share change QoQ
-2.2%
Holder tenure
15.4
Price vs estimated holder cost
-61.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
12.6%

Short interest

3 metrics
Short interest
9.8%
Latest settlement · 25.9 days to cover
Days to cover
25.9d
Short-squeeze score
73 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1593899 CUSIP 04683R106 13F (30d) 16 filings 16 filers Visit website Investor relations